In this article
The short answer
Allergy tested skincare needs more than a lab certificate on file. Keep the full study report, the protocol, the panel details, a sample identification that names the formula version tested, the ethics basis, the laboratory's own conclusion and a one-page claim record listing your exact wording and its limits. It sits in the Product Information File for ten years after the last batch, and any change to fragrance, preservative or a known sensitiser means checking the study still applies.
Key takeaways
- The legal duty is to hold adequate and verifiable evidence for the claim in the Product Information File, for ten years after the last batch is placed on the market.
- A one-page certificate is a summary, not evidence. The protocol, panel, readings and signed conclusion make a study verifiable.
- The tested sample must be traceable to the formula version on sale. Put the version number on the study request so the laboratory records it.
- A one-page claim record per claim (wording, where used, evidence, limits, review trigger) is the cheapest and most useful document in the file.
- Changes to fragrance, preservative or any known sensitiser usually break the link to the study. Record a decision for every change, retest or not.
- In GB the file is held at the address notified to OPSS, in English; in the EU at the Responsible Person's label address. Each Responsible Person needs a full copy.
Here is a scene we see again and again. A retailer's compliance team stalls a new listing because the buyer wants substantiation for the "allergy tested" badge on a night serum. The brand sends what it has: a one-page certificate from 2022 saying a repeat patch test found "no evidence of sensitisation". Two questions from the retailer end the matter. Which formula was tested? And has the serum changed since? The certificate describes the sample as "night serum, 30 ml". The serum got a new preservative system in 2024. Nobody wrote down whether the old study still applied, so as far as anyone can prove, it does not.
That is the usual way an allergy tested claim fails. Not because there was no test, but because the paper trail cannot connect the test to the product on the shelf. This guide is about that paper trail: what goes in the file, how to keep the link to the formula alive, and what happens when someone asks to see it. If you want to understand the test itself and which claims it can carry, start with our guide to the HRIPT test and allergy tested, hypoallergenic and dermatologist tested claims. For what hypoallergenic means for a formulator, see our guide to hypoallergenic cosmetics and compliance.
What the law asks you to hold
Two rules combine. Article 11 of Regulation (EC) No 1223/2009 requires the Responsible Person to keep a Product Information File for every product, and point (2)(d) says it must contain "where justified by the nature or the effect of the cosmetic product, proof of the effect claimed". Then the common criteria in Regulation (EU) No 655/2013 require every claim, explicit or implied, to be "supported by adequate and verifiable evidence". Where studies are used, they have to be relevant to the product and the benefit claimed, follow well designed and well conducted methods, and respect ethical considerations.
"Verifiable" does most of the work. Evidence is verifiable when someone outside your business can read it and follow how the conclusion was reached. A certificate that states a result without the method fails that test. So does an email from a supplier saying a raw material "has been tested".
The Commission's Technical document on cosmetic claims adds a line every brand with a tested claim should pin above the desk. The Responsible Person "should ensure that the evidential support is still applicable when the formulation of the product changes." The document is guidance rather than law, and the Commission's cosmetics legislation page still lists the version of 3 July 2017 as current, but enforcement officers and safety assessors use it as the benchmark.
Where the file lives depends on the market, and the Great Britain text is not a copy of the EU one:
| Great Britain | EU (and Northern Ireland) | |
|---|---|---|
| Who holds the file | A Responsible Person established in the United Kingdom | A Responsible Person established in the EU, or in Northern Ireland for products placed on the NI market |
| Where it is kept | At the address notified to OPSS under Article 13 as the place the file is kept | At the Responsible Person's address shown on the label |
| Language | English | A language the competent authority of the Member State where it is kept can easily understand |
| How long | 10 years after the last batch was placed on the market | 10 years after the last batch was placed on the market |
| Claims evidence | Article 11(2)(d): proof of the effect claimed, where the nature or effect of the product justifies it | Same wording |
The GB point catches people out. After the GB amendments, Article 11(3) no longer refers to the address on the label. The file must be accessible at the address you gave OPSS in the notification as the place the file is kept (Article 13(1)(c)). In many businesses that is the same address, but if your Responsible Person keeps files somewhere else, the notification is what counts. The GOV.UK guidance for Great Britain sums up the duty plainly: the Responsible Person must "be able to prove that any claims made when marketing the product are correct".
The seven documents in an allergy tested file
For one product with one allergy tested claim, a complete file has seven parts. Take any of them away and the claim becomes an assertion.
| Document | What it has to show | The gap we find most often |
|---|---|---|
| 1. Full study report | Study number, dates, laboratory, objective, results, interpretation, statistics and the signature of the person in charge | Only a one-page certificate on file |
| 2. Protocol | Induction and challenge schedule, patch type, occlusion, amount applied, reading times and the scoring scale | Never requested, so nobody can check how the result was reached |
| 3. Panel description | Number recruited and number who completed, inclusion and exclusion criteria, withdrawals and why | Recruited number quoted in marketing instead of completers |
| 4. Sample identification | Product name, formula version or batch number, and the dilution or concentration tested | Sample described as "face cream, white jar" |
| 5. Ethics and consent | Ethics approval reference where one applies, and confirmation of informed consent | Missing from summary certificates |
| 6. The laboratory's conclusion | The exact wording of the conclusion, plus any caveats or limitations | Conclusion paraphrased by the brand, more strongly than written |
| 7. Claim record | Every phrase used, where it appears, the evidence for it, its limits and what would trigger a review | Does not exist |
The first six come from the laboratory, if you ask for them. The technical document's best practice section expects a study report to include "clear identification of the product, enabling establishment of a link to the product available on the market", along with the objective, test schedule and protocol, results and interpretation, statistics and the signature of the person in charge. If your laboratory only sent a certificate, ask for the full report. The certificate was written from it, so it exists.
The seventh is yours, and almost nobody has it. It is also the cheapest document in the file.
A claim record you can copy
A claim record is one page per claim. It turns a folder of documents into an argument, which is what a reviewer is actually looking for. Here is the format we use, filled in for an illustrative serum:
| Field | Example entry (illustrative) |
|---|---|
| Claim wording | "Allergy tested" with the line "No sensitisation seen in a 52-person repeat patch study" |
| Where it appears | Carton front panel, product page, marketplace listing bullet 3, retailer copy supplied March 2026 |
| Evidence | HRIPT report ref. HR-25-0412, signed 14 May 2025; 55 recruited, 52 completed; occlusive patch, product tested neat |
| Product link | Report sample ID lists formula BR-SER-04 batch 25-118. Formula on sale: BR-SER-04 (no changes since) |
| Limits | Shows no induced sensitisation in 52 people. Does not cover people already allergic to an ingredient. Not a hypoallergenic claim. Not a sensitive skin claim (general panel) |
| Review trigger | Any change to fragrance, preservative, or an ingredient with known sensitising potential; any new wording |
| Signed off | Responsible Person, 2 June 2025; safety assessor consulted on wording |
Three fields do the heavy lifting. "Where it appears" matters because the same claim on your website, a marketplace listing, a retailer's copy or an influencer brief carries the same evidence burden as the carton; Article 20 covers labelling, making available and advertising alike. "Limits" forces you to write down what the study does not show before somebody else points it out. And "Review trigger" connects the claim to your change control, which is where most claims quietly die.
Writing the limits line is also the fastest way to find a claim that cannot be supported. A brand that sells a fragranced cream as allergy tested and hypoallergenic usually discovers, halfway down the page, that the study supports the first badge and nothing in the file supports the second.
Tying the tested sample to the product on sale
A study tests a sample. The claim is made about a product. The only thing joining them is a formula reference, and it has to appear in two places: in the laboratory's sample identification, and in your file against the formula version on sale. If either end is missing, the link rests on memory.
- Give every formula a version number and never reuse one. BR-SER-04 stays BR-SER-04 forever; the next change is BR-SER-05.
- Put the formula version and batch number on the study request, so the laboratory copies them into its own sample identification.
- Keep a one-line history for each product showing which versions the study covers.
- Make the version number visible on your batch records, so anyone can trace a jar on the shelf back to a version and then to a study.
If you already sell a product with a study that names no version, all is not lost. Find the batch record for the sample sent (the date of dispatch usually narrows it down), write a note connecting it to a formula version, and have it countersigned by whoever made the batch. It is weaker than a reference in the report, but far stronger than nothing.
Change control: which changes break the claim
Reformulation is the most common reason an allergy tested claim becomes unsupported. The product looks the same, performs the same and carries the same badge, but the study was done on something else. A change to the fragrance, the preservative system or any ingredient with known sensitising potential is the usual culprit. Other changes may not matter, but the judgement has to be written down, not assumed. As a working guide:
| Change to the product | Effect on the allergy tested claim | What goes in the file |
|---|---|---|
| New fragrance, or the supplier reformulates the same fragrance | Usually breaks the link. Fragrance ingredients are among the most common causes of contact allergy to cosmetics | Retest, or a written justification from the safety assessor if the change is genuinely trivial |
| Preservative system changed | Usually breaks the link. Several preservatives are known sensitisers | Retest or assessor justification, dated, before the new batch ships |
| Ingredient with known sensitising potential added, or its level raised | Breaks the link | Retest before using the claim on the new version |
| Surfactant or emulsifier changed | Often relevant, especially if levels or type change | Assessor decision recorded either way |
| Raw material supplier changed, same INCI and specification | Often no effect, but impurity profiles differ | Supplier specification compared, decision recorded |
| Colourant change within a shade range, small thickener adjustment | Often no effect | One-line note of the judgement and who made it |
| New pack format or new manufacturer, same formula | No effect on the formula, but confirm it really is the same formula | Note linking the new format or site to the existing version number |
Fragrance needs particular care because the change may not be yours. Fragrance houses adjust compounds to meet new IFRA standards or when a material becomes scarce, sometimes under the same product code. Put a clause in your supply agreement requiring notice of any change, and ask for an updated allergen statement each time. Our guide to the supplier documents behind a skin safe formula explains what those statements contain.
Build the trigger into whatever change procedure you already run. The simplest version is one extra question on the change form: does this change affect fragrance, preservative or any known sensitiser, and does the product carry a tested claim? If both answers are yes, the claim is suspended on the new version until the safety assessor has decided, in writing, whether to retest. The safety report has to be reviewed after a reformulation anyway, so the two decisions can be made together.
Commission the study so the report fits the file
Most of the gaps we find were created on the day the study was ordered. A test booked by email, with a jar posted and no written brief, produces a report that identifies the sample as a jar. The laboratory is not at fault. It recorded what it was given. A one-page study request fixes most of this:
- Product name, formula version and the batch number of the sample.
- The exact claim you intend to make, in the words you intend to print, with a request that the laboratory confirm the proposed design can support them.
- Whether you want a sensitive skin panel, if you plan to say anything about sensitive skin.
- The full report and protocol as deliverables, not a certificate.
- How a borderline or equivocal result will be reported, so you know in advance what you can and cannot claim.
Ask that last question before any money changes hands. A brand that has already printed cartons has every reason to read an ambiguous conclusion generously, which is exactly the situation the evidential support criterion exists to prevent.
Documents that do not prove the claim
Brands often offer the wrong document in good faith. Four come up again and again.
The safety report. The Cosmetic Product Safety Report is a toxicological assessment of the formula under Article 10 and Annex I, signed by a qualified safety assessor. It concludes that the product is safe under normal and reasonably foreseeable use. It is not a test, and it does not show that the product was allergy tested. It belongs in the file, but it is not the evidence for this claim. Our article on the difference between the PIF and the CPSR explains how the two fit together.
Supplier data on one ingredient. A raw material supplier may hold an HRIPT on its ingredient. That can support the safety assessment, but "allergy tested" on your pack tells shoppers the finished product was tested. The common criteria say a claim extrapolating ingredient properties to the finished product needs its own adequate and verifiable evidence, and an ingredient study does not show how the whole formula behaves.
A certificate with no method. As above, a result without a protocol is not verifiable.
An approval letter. No authority approves a tolerance claim, and no regulator issues a certificate for one. If somebody sells you an "allergy approved" mark, the mark itself is a claim that needs evidence.
When a retailer asks, and when Trading Standards asks
These two requests look alike and test different things. A retailer or marketplace usually works from a fixed list: safety report, Responsible Person details, notification, label artwork, perhaps insurance and a declaration of compliance, and substantiation for any claim on the pack. The reviewer is checking that every box has a document in it. Lists vary by platform and change without notice, so check the current version with each one. Our article on the compliance documents marketplaces ask for covers the typical contents.
An enforcement officer asks a question instead: show me the Product Information File, or show me how you support this claim. The officer is checking whether the evidence supports the words, which is a harder test. A complete set of files can still fail it if the wording goes further than the study. In Great Britain, failing to produce a document or record when an enforcement officer requires it is itself an offence under regulation 12(2)(d) of the Cosmetic Products Enforcement Regulations 2013, quite apart from any problem with the claim. Our guide to preparing for a Trading Standards inspection covers how those requests arrive.
Two habits help with both. Keep a standing retailer pack, built from the same source files as the PIF, so onboarding does not mean fresh work each time. Send the claim record and the study report, not your full formula; a buyer rarely needs the quantitative formula, and you should not hand it over without a reason. And keep the claim records current, so that when an officer asks, the answer already exists.
Selling in Great Britain, the EU, Northern Ireland and the US
The substance is the same in Great Britain, the EU and Northern Ireland, so one well built evidence set normally serves all three. What differs is who holds it and where. A GB product needs a UK Responsible Person holding the file at the notified address. A product placed on the EU market needs a Responsible Person established in the EU, and for Northern Ireland, GOV.UK guidance confirms the Responsible Person must be established in Northern Ireland or the EU.
So the same claims evidence may need to sit in two places under two parties' control. Write it once, index it, and give each Responsible Person a complete copy rather than a promise that you will send it when asked. If a service provider holds the role for you, make holding and producing the claims section an explicit term of the mandate. Our article on selling cosmetics in Northern Ireland explains the Windsor Framework position.
In the US there is no Product Information File, but the logic is the same. The FTC's Health Products Compliance Guidance says advertisers must have a reasonable basis for their claims before disseminating an ad. In other words, the evidence has to exist before the claim goes live, not be assembled after a complaint. The same file, with the same claim record, does the job.
Organise the claims section so it survives a request
Inside the Product Information File, keep a claims section with one subfolder per claim. In each subfolder, put the claim record first, then the study report, the protocol, the sample identification and formula version note, and finally any correspondence that qualifies the conclusion. Date everything. Keep superseded versions rather than overwriting them, because a question about a product sold two years ago is a question about the evidence that existed then, and the file has to survive for ten years after the last batch anyway.
For the layout of the whole file rather than the claims section, our Product Information File template and checklist gives the structure, and our worked Product Information File example shows a populated claims table. Build the claims section into that structure from the start, not as an attachment added the week a buyer asks. For substantiation more broadly, see how claim substantiation works from lab test to legal file.
Would your allergy tested file survive a request tomorrow?
Send us the study you hold, the formula history and every place the claim appears. We check that the tested sample matches the formula on sale, list what is missing from the file, draft the claim record and tell you whether the wording on your pack and listings stays inside the evidence. It costs far less than finding the gap during a retailer review or an inspection.
Related reading
- HRIPT test explained: what it proves for allergy tested, hypoallergenic and dermatologist tested claims
- Hypoallergenic cosmetics: safety, compliance and what it really means
- How can I find cosmetics that are genuinely hypoallergenic?
- Cosmetic claims: the common criteria and substantiation
- Cosmetic PIF template and checklist
- Preparing your cosmetic business for a Trading Standards inspection
- All regulatory compliance articles
Myths we hear
- The laboratory certificate is our proof. A result without a method is not verifiable. Ask for the full report and protocol and keep them in the file.
- Our safety report covers the allergy tested claim. The CPSR assesses the formula's safety under Article 10 and Annex I. It is not a test and does not substantiate a claim that a test was done.
- A small tweak to the formula does not matter. It might not, but the technical document expects you to check that the evidence still applies when the formulation changes. A change to fragrance, preservative or a sensitiser usually matters.
- Only the carton needs substantiating. Article 20 covers labelling, making available and advertising. The claim on your website, a marketplace listing or an influencer brief needs the same evidence.
- The lab or manufacturer can keep the evidence for us. They can hold copies, but the Responsible Person must keep the Product Information File accessible to the authorities. Relying on someone else's only copy is how deadlines get missed.
What to do this week
- List every product whose pack, website, listings or retailer copy says allergy tested or anything close to it.
- For each, get the full study report and protocol from the laboratory if you only hold a certificate.
- Check the sample identification names a formula version, and match it to the version on sale.
- Write a one-page claim record for each claim: wording, where used, evidence, limits, review trigger.
- Search your change log for fragrance, preservative or sensitiser changes since the study, and record a decision for each.
- Add a tested-claim question to your change form, so future reformulations trigger a review automatically.
- Put the set into a claims section of the PIF and send a complete copy to each Responsible Person (UK and EU).
- Remove or reword any claim you cannot evidence today, before a buyer or an officer finds it.
Frequently asked questions
What evidence do I need for an allergy tested claim?
The full study report with its protocol, panel description, sample identification, ethics basis and signed conclusion, plus a claim record of the exact wording it supports. It all belongs in the Product Information File.
Is a one-page laboratory certificate enough?
No. Evidence must be verifiable, meaning someone outside your business can follow how the conclusion was reached. A result stated without the method does not meet that standard, so ask the laboratory for the complete report.
How long do I have to keep the evidence?
The Product Information File must be kept for ten years after the last batch of the product was placed on the market, in both the GB and EU texts of Article 11. Keep the claims evidence for at least as long.
Where must the file be kept in Great Britain?
At the address the Responsible Person notified to OPSS as the place the Product Information File is kept, and in English. Under the EU text it is the Responsible Person's address shown on the label.
Does a reformulation mean testing again?
Not always, but you must decide and record whether the study still applies. A change to the fragrance, the preservative system or any known sensitiser usually needs fresh evidence or a written justification from the safety assessor.
Can I say allergy tested if only an ingredient was tested?
No. Shoppers read it as a claim about the finished product. Ingredient data can support the safety assessment, but the common criteria require adequate evidence when ingredient properties are extrapolated to the product.
What will a retailer ask me for?
Usually a fixed list: safety report, Responsible Person details, notification, label artwork and substantiation for any claim on the pack, sometimes insurance too. Lists vary by platform, so confirm the current one and build the pack from your indexed source files.
What happens if I cannot produce the evidence?
The claim is unsupported, which breaches the claims rules. You may have to withdraw the wording, relabel or delist, and in GB failing to produce a document an enforcement officer requires is itself an offence.
Official sources and legislation
- Regulation (EC) No 1223/2009, Article 11 (Product Information File), as it applies in Great Britain, legislation.gov.uk
- Regulation (EC) No 1223/2009, Article 11, original text as adopted by the EU (label address, language)
- Regulation (EC) No 1223/2009, Article 13 (GB notification, address where the PIF is kept), legislation.gov.uk
- Regulation (EC) No 1223/2009, Article 20 (product claims), legislation.gov.uk
- Commission Regulation (EU) No 655/2013, Annex (common criteria), as it applies in Great Britain, legislation.gov.uk
- Commission Regulation (EU) No 655/2013, Annex, original text as adopted by the EU
- Technical document on cosmetic claims, version of 3 July 2017
- European Commission: cosmetics legislation page listing the technical document on claims
- Cosmetic Products Enforcement Regulations 2013
- Cosmetic Products Enforcement Regulations 2013, regulation 12 (offences)
- GOV.UK: Making cosmetic products available to consumers in Great Britain
- FTC: Health Products Compliance Guidance
Join the conversation